Following the United Kingdom toward ever-greater state control over drug pricing will squander our nation’s economic and scientific advantages — and leave patients with far fewer new cures.
Drug companies are fleeing the United Kingdom. This month, Merck announced that it would cancel a proposed $1.3 billion research center in London and terminate all of its research and development efforts in the country.
To justify its decision, the drugmaker cited “the overall undervaluation of innovative medicines and vaccines by successive UK governments.”
Those governments systematically undervalue medicines by slapping price controls on them. And those decisions have made the country inhospitable to medical progress.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Drug Innovation is Dying in UK, Don’t Let it Happen Here
Sally C. Pipes
Following the United Kingdom toward ever-greater state control over drug pricing will squander our nation’s economic and scientific advantages — and leave patients with far fewer new cures.
Drug companies are fleeing the United Kingdom. This month, Merck announced that it would cancel a proposed $1.3 billion research center in London and terminate all of its research and development efforts in the country.
To justify its decision, the drugmaker cited “the overall undervaluation of innovative medicines and vaccines by successive UK governments.”
Those governments systematically undervalue medicines by slapping price controls on them. And those decisions have made the country inhospitable to medical progress.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.